Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CERT Stock Forecast 2026-2027
$5.37
Current Price
$835.38M
Market Cap
Buy 5
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to CERT Price Targets
+86.2%
To High Target of $10.00
+49.0%
To Median Target of $8.00
+11.7%
To Low Target of $6.00
CERT Price Momentum
-12.3%
1 Week Change
-14.9%
1 Month Change
-54.3%
1 Year Change
-39.0%
Year-to-Date Change
-61.3%
From 52W High of $13.88
+20.7%
From 52W Low of $4.45
📊 TOP ANALYST CALLS
Did CERT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Certara is one of their latest high-conviction picks.
Latest CERT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, CERT has a neutral consensus with a median price target of $8.00 (ranging from $6.00 to $10.00). The overall analyst rating is Buy (7.7/10). Currently trading at $5.37, the median forecast implies a 49.0% upside. This outlook is supported by 5 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Laaman at Morgan Stanley, projecting a 86.2% upside. Conversely, the most conservative target is provided by Sean Dodge at BMO Capital, suggesting a 11.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CERT Analyst Ratings
5
Buy
7
Hold
0
Sell
CERT Price Target Range
Low
$6.00
Average
$8.00
High
$10.00
Current: $5.37
Latest CERT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CERT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2026 | Craig-Hallum | Matthew Hewitt | Hold | Maintains | $8.00 |
| May 12, 2026 | BMO Capital | Sean Dodge | Market Perform | Maintains | $6.00 |
| May 12, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $6.50 |
| May 12, 2026 | Stephens & Co. | Jeff Garro | Overweight | Maintains | $9.00 |
| May 12, 2026 | Morgan Stanley | Sean Laaman | Equal-Weight | Maintains | $10.00 |
| May 12, 2026 | Baird | Joe Vruwink | Neutral | Maintains | $6.00 |
| Apr 13, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Mar 6, 2026 | Barclays | Equal-Weight | Downgrade | $N/A | |
| Feb 27, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 8, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Jan 6, 2026 | Leerink Partners | Outperform | Upgrade | $N/A | |
| Dec 18, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 15, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 12, 2025 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Nov 13, 2025 | BMO Capital | Market Perform | Initiates | $N/A | |
| Nov 7, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Oct 8, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Oct 2, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Sep 29, 2025 | Craig-Hallum | Buy | Initiates | $N/A | |
| Aug 7, 2025 | UBS | Buy | Maintains | $N/A |
Certara, Inc. (CERT) Competitors
The following stocks are similar to Certara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Certara, Inc. (CERT) Financial Data
Certara, Inc. has a market capitalization of $835.38M with a P/E ratio of 105.0x. The company generates $419.75M in trailing twelve-month revenue with a -3.6% profit margin.
Revenue growth is +0.9% quarter-over-quarter, while maintaining an operating margin of +3.8% and return on equity of -1.4%.
Valuation Metrics
Market Cap
$835.38M
Enterprise Value
$990.53M
P/E Ratio
105.0x
PEG Ratio
-0.4x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
+0.9%
Gross Margin
+61.1%
Operating Margin
+3.8%
Net Margin
-3.6%
EPS Growth
+0.9%
Financial Health
Cash/Price Ratio
+17.9%
Current Ratio
1.9x
Debt/Equity
30.0x
ROE
-1.4%
ROA
+0.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Certara, Inc. (CERT) Business Model
About Certara, Inc.
What They Do
Provides biosimulation technology for drug development.
Business Model
Certara generates revenue by offering proprietary biosimulation platforms, software products, and expert consulting services to biopharmaceutical and biotech organizations. Their solutions help clients design clinical trials, optimize drug development decisions, and expedite regulatory approvals, making them integral to the drug development process.
Additional Information
The company serves over 2,600 life sciences organizations, including 38 of the top 40 biopharmaceutical companies, contributing to the majority of novel drug approvals from the FDA. In 2024, Certara enhanced its capabilities by acquiring Chemaxon, focusing on improving drug discovery through advanced chemical property prediction and in-silico development tools. With a global presence and a commitment to integrating AI within scientific frameworks, Certara is positioned for continued growth in the evolving life sciences sector.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,515
CEO
Mr. Jon Resnick
Country
United States
IPO Year
2020
Website
www.certara.comCertara, Inc. (CERT) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors in Certara, Inc. (NASDAQ: CERT). Affected investors can contact Danielle Peyton for more information.
Why It Matters
The investigation into Certara raises concerns about potential legal issues, which may affect the company's stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Certara, Inc. (CERT) presented at the Jefferies Global Healthcare Conference, highlighting key developments and insights relevant to investors.
Why It Matters
Certara's presentation at a major healthcare conference signals potential developments in its pipeline or strategies, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cerrado Gold Inc. (CERT:CA) held its Q1 2026 earnings call, providing insights into financial performance and operational updates. Further details are available in the transcript.
Why It Matters
Cerrado Gold's earnings call reveals financial performance, strategic updates, and market outlook, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
15 days ago
Quick Summary
The Schall Law Firm is investigating Certara, Inc. (NASDAQ: CERT) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters
The investigation into Certara for potential securities law violations may signal risks of legal troubles, impacting share value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kirby McInerney LLP is investigating Certara, Inc. (NASDAQ:CERT) for potential violations of federal securities laws by the company or its senior management.
Why It Matters
The investigation into Certara could indicate potential legal risks and regulatory scrutiny, potentially impacting the company's stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
20 days ago
Quick Summary
Certara, Inc. (CERT) presented at the RBC Capital Markets Global Healthcare Conference, discussing its strategies and outlook for 2026.
Why It Matters
Certara's presentation at a major healthcare conference can influence investor sentiment, provide insights into future growth, and affect stock performance based on strategic direction and innovation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CERT Stock
What is Certara, Inc.'s (CERT) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Certara, Inc. (CERT) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.
Is CERT stock a good investment in 2026?
According to current analyst ratings, CERT has 5 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CERT stock?
Wall Street analysts predict CERT stock could reach $8.00 in the next 12 months. This represents a 49.0% increase from the current price of $5.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Certara, Inc.'s business model?
Certara generates revenue by offering proprietary biosimulation platforms, software products, and expert consulting services to biopharmaceutical and biotech organizations. Their solutions help clients design clinical trials, optimize drug development decisions, and expedite regulatory approvals, making them integral to the drug development process.
What is the highest forecasted price for CERT Certara, Inc.?
The highest price target for CERT is $10.00 from Sean Laaman at Morgan Stanley, which represents a 86.2% increase from the current price of $5.37.
What is the lowest forecasted price for CERT Certara, Inc.?
The lowest price target for CERT is $6.00 from Sean Dodge at BMO Capital, which represents a 11.7% increase from the current price of $5.37.
What is the overall CERT consensus from analysts for Certara, Inc.?
The overall analyst consensus for CERT is neutral. Out of 7 Wall Street analysts, 5 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are CERT stock price projections?
Stock price projections, including those for Certara, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 6:57 AM UTC